Last reviewed 2026-05-30 · How we verify

Panavital

Petteri Hirvonen · Phase 1 active Small molecule ✓ Verified May 2026

Panavital is a Small molecule drug developed by Petteri Hirvonen. It is currently in Phase 1 development. Also known as: D-glyceric acid calcium salt dehydrate.

Panavital is a molecule being studied for its potential therapeutic effects, specifically in the context of exercise and energy metabolism. A clinical trial (NCT04713319) is investigating the acute health effects of Panavital in physically active individuals, comparing it to a placebo and a bout of exercise.

Likelihood of approval

9.6% vs 9.6% industry baseline

If approved by FDA: likely 2033–2036

Steps remaining: Phase 2 → Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 1 → approval rate +9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2033–2036	—
EMA	EU	2034–2037	+0.7 yr
MHRA	GB	2034–2037	+0.7 yr
Health Canada	CA	2034–2038	+0.9 yr
TGA	AU	2034–2038	+1.2 yr
PMDA	JP	2034–2038	+1.5 yr
NMPA	CN	2035–2039	+2.3 yr
MFDS	KR	2034–2038	+1.4 yr
CDSCO	IN	2034–2039	+1.8 yr
ANVISA	BR	2035–2039	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	Panavital
Also known as	D-glyceric acid calcium salt dehydrate
Sponsor	Petteri Hirvonen
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Novel Energy Metabolic Signaling Molecule With Therapeutic Potential (EARLY_PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Panavital CI brief — competitive landscape report
Panavital updates RSS · CI watch RSS
Petteri Hirvonen portfolio CI

Frequently asked questions about Panavital

What is Panavital?

Panavital is a Small molecule drug developed by Petteri Hirvonen.

Who makes Panavital?

Panavital is developed by Petteri Hirvonen (see full Petteri Hirvonen pipeline at /company/petteri-hirvonen).

Is Panavital also known as anything else?

Panavital is also known as D-glyceric acid calcium salt dehydrate.

What development phase is Panavital in?

Panavital is in Phase 1.

Manufacturer: Petteri Hirvonen — full pipeline
Therapeutic area: All drugs in Other
Also known as: D-glyceric acid calcium salt dehydrate

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing